Isabel Ortega-Madueño

Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217–based assessment of CSF amyloid positivity in secondary-care patients with MCI

Plasma p-tau217 accurately reflects amyloid pathology, but dual-cutoff strategies leave a non-negligible grey zone requiring confirmatory testing. We evaluated whether integrating plasma Aβ measurements could reduce diagnostic uncertainty in patients with mild cognitive impairment (MCI). Plasma p-tau217 was...